Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (February 2026)
45 slides from Genelux's investor presentation, Feb 2, 2026
Slide 1: Redefining Immuno-Oncology
GeENELUX Redefining Immuno-Oncology Corporate Presentation February 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Genelux Corporatio
Slide 3: Highlights
Highlights Ongoing pivotal Phase 3 trial in late-stage platinum resistant/refractory ovarian cancer (PRROC) >>> Alignment reached with FDA that could potentially support a traditional approval without need for confirmatory trial Ongoing Phase 2 trial via systemic administration in recurrent non-smal
Slide 4: A Maturing Modality with Phase Companies Validating Oncolytic Virus Potential
A Maturing Modality with Phase 3 Companies Validating Oncolytic Virus Potential @ene_ux> Systemic Next Generation Delivery Regional & Systemic Administration Phase 2 Ovarian Cancer Limitations of 1st Gen Viruses ; Phase 1b Solid Tumors Limited to local delivery and scope of addressable cancers AMGEN
Slide 5: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred routes of delivery Regional and Systemic Administration to preferentially locate, colonize and destroy tumor cells, including metastatic disease IV therapy currently
Slide 6: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages Upcoming Trial Readouts have Potential to Redefine: > Therapy (platinum resensitization in multiple indications) > Modality (systemic administration of an oncolytic virus) failure) inhibitor-based regimen data expected throughout 2
Slide 7: Regional Administration Program: Ovarian Cancer
(eENELUX > Regional Administration Program Ovarian Cancer
Slide 8: Ovarian Cancer Program: Regional (Intraperitoneal) Delivery
Ovarian Cancer Program: Regional (Intraperitoneal) Delivery Key Takeaways IN * Phase | tested condensed dosing schedule and demonstrated tolerability with evidence of anti- tumor activity * Phase 2 demonstrated promising Overall Response Rate (ORR) and Progression Free Survival (PFS), and clinical r
Slide 9: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance/refractoriness. Key Inclusion Crite: Multi-center, randomized open-label! Primary Endpoint n=186 » High-g
Slide 10: Completed Phase 1b Anti-tumor Activity as Monotherapy Leading into Combination
Completed Phase 1b Anti-tumor Activity as Monotherapy Leading into Combination Key Clinical Takeaways Median progression free survival (mPFS) of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus monotherapy — the dose used in Phase 2. 1. SOC-AURELIA regimen (1-2
Slide 11: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec- primed Immunochemotherapy » High-grade serous, endometrioid or clear-cell ovarian cancer including: (1) platinum-resistant (recurrence or progression in < 6 months) or (2) platinum-refractory (progression while on platinum-based therapy) with at least two prior lin
Slide 12: Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients
Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients Key Clinical Takeaways IN Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC All patients had documented progressive disease at enrollment + The mPFS of the patients’
Slide 13: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage > > ® > > ? a a DP m3 > - - a os s - ea oF s FF SK Pal ra a iN x 100 133.24 58 81 62 132 19 46 45 53 129 31 253 70 124 48 145 65 138 83 82 12 Key Clinical Takeaways 2 80 Baseline tumor burden as Sum of Longest Diameter of target lesions (
Slide 14: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, 15B-01: Stage IIIB papillary serous ECOG: 0 BRCA negative PD-L1 negative Overall Survival: 23.2 Months 8 Failed 9 Prior Lines achieved PFS exceeding any prior lines 15B-
Slide 15: Meaningful clinical benefit: Relative to patients’ preceding line of therapy
Meaningful clinical benefit: Relative to patients’ preceding line of therapy NN Key Clinical Takeaways Promising PFS and clinical reversal of platinum resistance and refractoriness among patients with PRROC + All patients had documented progressive disease at enrollment + The mPFS of the patients’ i
Slide 16: Durable Survival Benefit
Durable Survival Benefit NN Key Clinical Takeaways Encouraging mOS and Long-termsurvival data 20% long-term survivors consistent with clinically beneficial immunotherapies * Onamedian 5th line of treatment, VIRO-15 Phase 2 patients achieved a m0OS of 15.7 mos + 4of 6 long-term survivors were platinu
Slide 17: Phase 2 Compared to Approved Standard of Care in Earlier Lines
Phase 2 Compared to Approved Standard of Care in Earlier Lines Bevacizumab + Elahere Elahere Olvi-Vec Chemolhe! shy, Phase 3 Phase 2 Phase 2 AURELIA Study) (MIRASOL Study) (SORAYA Study) (VIRO-15 Study) . >» FRa positive and platinum-resistant Platinum resistant Key Clinical Ta keaways Patient Popul
Slide 18: Self Launch of Olvi-Vec for Ovarian Cancer in the US
Self Launch of Olvi-Vec for Ovarian Cancer in the US No Entrenched Competitorin 4‘ Line PRROC + Global revenues of advanced recurrent ovarian cancer drugs are expected to grow from USD 2.5 billion (2023) to USD 5.5 billion (2032)!. + Potential future label expansion in newly- diagnosed patients \ Co
Slide 19: Systemic Administration Programs: Lung Cancers
Systemic - <> Administration @eneL_ux Programs Lung Cancers
Slide 20: Systemic Administration Demonstrated Dose-dependent OS Benefit
Systemic Administration Demonstrated Dose-dependent OS Benefit Key Clinical Takeaways IN Demonstrated feasibility and clinical benefit of multiple IV cycles + Median 5 prior lines of therapy + Regimen: various dosing levels and schedules (typically over 4-6 months) + Duration of Treatment (DoT): Hig
Slide 21: Systemic Administration + Chemo Generated Encouraging Data
Systemic Administration + Chemo Generated Encouraging Data 3 Cancer - AdventHealth | Institute * Expanded Access Program Key Clinical Takeaways IN Platinum refractory metastatic High-grade pancreatic cancer with cervical cancer with lung mets lung & liver mets Anti-tumor effect of IV Gove Report saz
Slide 22: Systemic Administration Program
Systemic Administration Program Key Takeaways » Ongoing Clinical Trials * All patients in these ongoing clinical trials are treated systemically and previously failed platinum-based therapy a = ng Cancer Clinical Trial Initial Interim Data Sponsor Trial Sites Indication ae ae Randomization Status +
Slide 23: Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer
Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer Heavily Pretreated Patients with Platinum-Relapse or Platinum-Refractory Small Cell Lung Cancer Phase 1b, multi-center, dose escalation, open-label N = up to 36 Key Inclusion Criteria = ose Escalation C rts Phase 1b Endpoints Primary Endpoint - Sa
Slide 24: Phase 1b/2 SCLC Systemic Administration - Interim Data Readout
Phase 1b/2 SCLC Systemic Administration - Interim Data Readout As of data review cutoff date of December 23, 2025 Key Takeaways IN Data is suggestive of potential dose-response trend + 66% (2/3) achieved partial responses — (PR) in highest dose cohort tested as of data review cutoff date (tumor redu
Slide 25: Phase 2 Trial in Recurrent Non-small Cell Lung Cancer
Phase 2 Trial in Recurrent Non-small Cell Lung Cancer Patients with Non-small Cell Lung Cancer after First Progression while on Front-Line Immune Checkpoint Inhibitor-based Maintenance Key Inclu i e Advanced or metastatic NSCLC: Stage III or Stage IV e Nonsquamous or squamous disease e Without known
Slide 26: Phase 2 NSCLC Systemic Administration - Interim Data Readout
Phase 2 NSCLC Systemic Administration - Interim Data Readout As of data review cutoff date of December 31, 2025 Key Takeaways bh + Dose escalation cohorts achieved a 60% (3/5) disease control rate (3 stable disease (SD)) > 2 stable disease patients achieved composite tumor size reductions of 19% and
Slide 27: Industry Collaboration with Newsoara HYK Biopharmaceuticals Co., Ltd
Industry Collaboration with Newsoara HYK Biopharmaceuticals Co., Ltd @enecux > NEWSGARA 3 pREMER Benny Li, PhD Newsoara Founder and CEO 20+ yrs. global and China local pharma Former VP, GM of Takeda China Development Center and SVP, Executive >, GM of R&D at Hansoh Pharmaceuticals Former Head of Cli
Slide 28: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate a Patent Portfolio: 21 issued patents and 7 pending applications; ar patent term expected to extend into 2038 Strong IP ~~ Olvi-Vec: No third-party royalties due Regulatory Designations ~ qo Long Duration of Regulatory / Marketing Exclus
Slide 29: Integrated Capabilities For Phase 3 And Launch
Integrated Capabilities For Phase 3 And Launch Key Takeaways IN Facilities and Operations based in Southern California GMP Manufacturing » Large-scale manufacturing ess Wr ara, UsA process : _ * Capacity for clinical studies and commercial launch needs Translational Research * Clinical Science capab
Slide 30: Accomplished Leadership Team
Accomplished Leadership Team Executive Team @ ® JAMES L. TYREE, MBA Pfizer Lead Independent Director TH Abbott Thomas Zindrick, JD Matthew Pulisic, MBA Jason Litten, MD Eric Groen, JD hf Chief Executive Officer Chief Financial Officer Chief Medical Officer General Counsel & MARY MIRABELLI, MBA cS on
Slide 31: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Regular Cadence of Important Program Milestones - Upcoming Trial Readouts have Potential to Redefine: > Therapy (platinum resensitization in multiple indications) b > Modality (systemic administration of an oncolytic virus)
Slide 32: Appendix
GeENELUX Redefining Immuno-Oncology Corporate Presentation | February 2026 Appendix
Slide 33: Olvi-Vec Seeks to Unleash Immune System Against Cancer
Olvi-Vec Seeks to Unleash Immune System Against Cancer Key Takeaways IN Olvi-Vec is being developed as a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body and aims to: * Selectively replicate in tumors to kill cancer
Slide 34: Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance
Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance '-Vec-Induced Hot Tumor Pro-therapeutic gene expression Chemotherapy synergy [VIRO-15 Monotherapy Data] > Positive regulation of T-cell activating immunogenic cell death and ; and trafficking’ 3 N presentation of oncogenic neoantigens
Slide 35: Accomplished Clinical Advisory Board
Accomplished Clinical Advisory Board Robert Holloway, MD CHAIRMAN Robert Coleman, MD Albert A. Mendivil, MD Deputy Director of the University of Cincinnati Cancer Institute Thomas J. Herzog, MD David M. O'Malley, MD Forsythe & Bear, Alan Forsythe, PhD uc’ ©0960 Dr. Holloway is the principal investig
Slide 36: Olvi-Vec-Primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker
Olvi-Vec-Primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker Rapid, Common and Durable Responses CA-125 Decrease ORR by CA-125 © All PRROC Patients: 96% (25/26) © All PRROC Patients: 85% (22/26) o Platinum refractory patients: 85% (11/13) o Platinum refractory patients: 85% (11/13) Oe SS
Slide 37: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-15: Pt.15B-15 (primary platinum-refractory HGSOC) + Stage IIIB high- grade serous 160 5000 + ECOG:0 J Start of Chemo/Bevacizum
Slide 38: Olvi-Vec Demonstrated Oncolysis and Immune Activation
Olvi-Vec Demonstrated Oncolysis and Immune Activation Data from Phase 1b Monotherapy portion of VIRO-15 trial Key Takeaways » Olvi-Vec mono! yy shows decreased tumor cells and increased immune activation * Olvi-Vec treatment was able to dramatically decrease or eliminate tumor cells in multiple pati
Slide 39: CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival Pt# 15A-16 Pt# 15A-18 Pt# 15A-23 Pre-Olvi-Vec CcD4+ Post-Olvi-Vec (prior to subsequent chemotherapy) Endogenous TILs (intra-tumoral and stromal) are very low in ovarian Pt# 15A-18 Pt# 15A-23 cancer, i.e, immunologically ‘col
Slide 40: Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction
Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction Data from Phase 1b Monotherapy portion of VIRO-15 trial “ooo Confirms tumor-antigen presentation Case Report (Pt #15A-05) ‘000 | oaunne: man fl Key Takeaways N Heavily pre-treated: 3 ° = ae 9 prior regimens of chemo+ Avastin
Slide 41: Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed
Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed Data from Phase 1b Monotherapy portion of VIRO-15 trial Target lesion SLD change overtime Individual target lesion change = oP esp —O— PR 10 ° lesion size from bas “ S 3 [ S £ 3 3 aa iS 5 € — i) o cr) = c du So B o c) n 8 Patient I
Slide 42: Choice Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Therapeutic Cell Growth & Differentiation Regulators Hormones Genes Metastasis Suppressor Genes
Slide 43: Olvi-Vec & Cisplatin Demonstrate Activity in Animal Models with Platinum-resistant Cancer Lines
Olvi-Vec & Cisplatin Demonstrate Activity in Animal Models with Platinum-resistant Cancer Lines Synergistic and Durable Antitumor Activity Ovarian Cancer (OVCAR-3 cell line) Melanoma (WM266.4 cell line) 120 -eNo treatment 10000 + —®-Olvi-Vec alone ~t-Olvi-Vec + cisplatin = 8000 Cisplatin alone g 4 E
Slide 44: Olvi-Vec & anti-PD-1: Enhanced Activity in Immune-competent Animal Model
Olvi-Vec & anti-PD-1: Enhanced Activity in Immune-competent Animal Model Pre-clinical Support for Treatment-naive Resectable Non-small Cell Lung Cancer > Prolonged survival and enhanced anti-tumor activity from combination of oncolytic vaccinia virus Olvi-Vec (VV-ILP) and immune checkpoint inhibitor
Slide 45: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Therapy Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCT01443260/TUE Study Induction of acute inflammatory EB cytokines $ (Thi-type related) 3 3 VIRO-15 Study Massive inflammatory response after (C1D24) single dose of virus Baseline Endogenous P